STOCK TITAN

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2024 Results: February 8, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Haemonetics Corporation (NYSE: HAE) will release its third quarter fiscal year 2024 financial results on February 8, 2024, at 6:00 am ET, followed by a conference call at 8:00 am ET to discuss the results and answer questions. Investors and analysts can access the call via teleconference or live webcast on the company's investor relations website. A replay of the call will be available for one year.
Positive
  • None.
Negative
  • None.

BOSTON, Jan. 11, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, February 8, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 8, 2024.

The call can be accessed via teleconference at: Q3 2024 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.

A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/unynzc8w 

A replay of the conference call and webcast will be available for one year beginning on February 8, 2024 at 11:00 am ET using the conference call webcast link provided in this press release.

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts: 



Olga Guyette, Sr. Director-Investor Relations & Treasury   


David Trenk, Manager-Investor Relations

(781) 356-9763     


(203) 733-4987

olga.guyette@haemonetics.com     


david.trenk@haemonetics.com 




Media Contact: 



Josh Gitelson, Director-Global Communications



(781) 356-9776



josh.gitelson@haemonetics.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-sets-date-for-publishing-third-quarter-fiscal-year-2024-results-february-8-2024-302033140.html

SOURCE Haemonetics Corporation

Haemonetics Corporation (NYSE: HAE) will release its third quarter fiscal year 2024 financial results on February 8, 2024, at 6:00 am ET.

Investors and analysts can access the conference call via teleconference or live webcast on Haemonetics' investor relations website.

A replay of the conference call and webcast will be available for one year beginning on February 8, 2024, at 11:00 am ET.
Haemonetics Corp.

NYSE:HAE

HAE Rankings

HAE Latest News

HAE Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
US
Boston

About HAE

haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right